Project Grant R01CA300518
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$510K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
The federal Project Grant award R37CA288492, totaling $594,823, was awarded by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353). The objective of this 5-year grant is to determine the role of social determinants of health (SDOHs), including structural racism and individual socioeconomic position, on cardiovascular disease (CVD) outcomes among a cohort of cancer survivors.
The project will leverage data from the Reasons for...
This $1,027,816 Project Grant award from the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot) supports research to identify the impact of structural racism on mutational signatures and outcomes in African American patients with non-small cell lung cancer (NSCLC).
The research aims to determine how measurable structural racism stressors, such as air pollution and residential segregation, induce changes in mutational processes that affect disease...
The University of Alabama at Birmingham (UAB) was awarded a $661,845 Project Grant (R37CA296615) from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to examine the role of structural racism in racial and ethnic disparities in end-of-life (EOL) care quality for children with cancer.
The grant aims to: 1) Examine how structural racism contributes to disparities in EOL care quality; 2) Develop and validate a prediction model to identify children at risk of...
This $659,498 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to investigate racial disparities in the mechanisms of prostate cancer metastasis, with a primary focus on examining the roles of the FGFR3 signaling pathway and oxidative phosphorylation (OXPHOS) activity. The award was granted to Emory University, with sub-awards to Johns Hopkins University and Morehouse School of Medicine to assist with various...
The National Cancer Institute (NCI) awarded a $432,304 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Trustees of Columbia University in the City of New York, Health Sciences Division, to develop enhanced cancer risk prediction models for underrepresented Black and Hispanic populations. The 5-year project, beginning January 3, 2025, aims to create novel data integration methods that effectively leverage diverse data sources, including electronic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $362,050 to the University of Alabama at Birmingham (UAB) to conduct an integrated genomic-transcriptomic characterization study to identify molecular mechanisms underlying disparities in pancreatic ductal adenocarcinoma (PDAC) outcomes between African American and Caucasian patients.
The research aims to interrogate the mutational landscape of PDAC using whole...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $156,000.00 in funding to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, to conduct whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic castration-resistant prostate cancer (mCRPC). The goal is to identify race-specific mutational signatures and evaluate their associations with...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $539,633 to support research at Albert Einstein College of Medicine focused on investigating the role of aberrant androgen receptor signaling in prostate cancer development and progression, particularly in the African American population. The project aims to leverage new animal models and advanced techniques like single-cell RNA sequencing to study how genetic factors like shorter...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $589,459 to The Johns Hopkins University to conduct research on lung cancer health disparities in African American populations. The key focus is to: (1) identify a novel African American-specific non-coding RNA (AA-pcRNA) that is expressed in lung cancer tissue from African Americans but not Caucasians or Asians, and characterize its...
The National Cancer Institute (NCI) awarded a $789,579 Cooperative Agreement (CFDA 93.396 - Cancer Biology Research) to Emory University to conduct research on "Targeting Microbial Triggers of Gammopathy for Immunoprevention." The project, scheduled to run from June 2024 to May 2026, aims to characterize the gut microbes that may act as antigenic triggers for B cells, leading to monoclonal gammopathy and potentially multiple myeloma. The research will utilize newly developed...